Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
45.86 USD | +0.01% | -5.89% | +66.76% |
05-13 | Merus Says US FDA Grants Breakthrough Therapy Designation for Petosemtamab | MT |
05-13 | Merus Carcinoma Treatment Awarded US FDA's Breakthrough Therapy Designation | DJ |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+66.76% | 2.69B | |
+4.00% | 111B | |
+11.42% | 105B | |
-13.01% | 22.34B | |
-3.70% | 21.93B | |
-6.03% | 18.59B | |
-35.21% | 18.12B | |
-10.29% | 16.96B | |
+2.44% | 13.7B | |
+36.07% | 12.45B |
- Stock Market
- Equities
- MRUS Stock
- News Merus N.V.
- Citigroup Adjusts Price Target on Merus to $48 From $47, Keeps Buy Rating